Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature

Br J Haematol. 2020 Jan;188(2):338-340. doi: 10.1111/bjh.16333. Epub 2019 Dec 15.

Dikélélé Elessa^{1

2}, Alexis Talbot^{1

2}, Naëlle Lombion^{1

2}, Stéphanie Harel^{1

2}, Lionel Galicier^{2

3}, Agnès Veyradier^{2

4

5}, Bérangère Joly^{2

4

5}, Annalisa Andreoli⁶, Sophie Rigaudeau⁷, Élie Azoulay^{2

8}, Paul Coppo^{4

9}, Bruno Royer^{1

2}, Bertrand Arnulf^{1

2}

¹ Department of Immunohematology, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, Paris, France.
² University Paris Diderot Sorbonne Paris Cité, Paris, France.
³ Department of Clinical Immunology, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, Paris, France.
⁴ National Reference Center for Thrombotic Microangiopathy, Hôpital Saint-Antoine, Assistance Publique - Hôpitaux de Paris, Paris, France.
⁵ Department of Biological Hematology, Hôpital Lariboisière, Assistance Publique - Hôpitaux de Paris, Paris, France.
⁶ Department of Clinical Hematology, Centre Hospitalier Victor Dupouy, Argenteuil, France.
⁷ Department of Clinical Hematology, Centre Hospitalier Versailles, Le Chesnay, France.
⁸ Department of Intensive Care Medicine, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, Paris, France.
⁹ Department of Clinical Hematology, Hôpital Saint Antoine, Assistance Publique - Hôpitaux de Paris, Paris, France.

No abstract available

Keywords: ADAMTS13; lenalidomide; myeloma; thrombotic microangiopathy; thrombotic thrombocytopenic purpura.

Publication types